STUDY OF CAMPATH-1H COMBINED WITH MMF AND SIROLIMUS (PC01)

CAMPATH-1H 联合 MMF 和西罗莫司的研究 (PC01)

• 批准号: 7607267
• 负责人: WILLIAM E. HARMON
• 金额: $ 23.02万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607267
• 关键词: Calcineurin inhibitor; Cessation of life; Chronic; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Monoclonal Antibody Campath-1H; Research; Research Personnel; Resources; Safety; Sirolimus; Source; Steroids; Transplantation; Treatment Protocols; United States National Institutes of Health; fluorouracil/methotrexate/mitoxantrone protocol; mycophenolate mofetil; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objective To evaluate the safety of Campath-1H post-transplantation when given as part of a multitherapy regimen to prevent graft loss and death and to avoid steroids and chronic use of calcineurin inhibitors.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 主要目标 评估 Campath-1H 移植后作为多重治疗方案的一部分给予的安全性，以防止移植物丢失和死亡，并避免类固醇和长期使用钙调神经磷酸酶抑制剂。